Results 51 to 60 of about 964 (170)

Effects of baseline symptom burden on treatment response in COPD

International Journal of COPD, 2019
Fernando J Martinez,1 Roger A Abrahams,2,3 Gary T Ferguson,4 Leif Bjermer,5 Lars Grönke,6 Florian Voß,7 Dave Singh8 1Division of Pulmonary and Critical Care Medicine, Weill Cornell Medical College, New York, NY, USA; 2Morgantown Pulmonary ...
Martinez FJ, Abrahams RA, Ferguson GT, Bjermer L, Grönke L, Voß F, Singh D   +6 more
doaj  

Systematic review comparing LABA, olodaterol, and indacaterol: limitations

International Journal of Chronic Obstructive Pulmonary Disease, 2014
James F Donohue Pulmonary Diseases and Critical Care Medicine, UNC School of Medicine, Chapel Hill, NC, USA Dear editor Roskell et al present a systematic review comparing the long-acting beta2 agonists (LABA), olodaterol, and indacaterol in the July edition of the International Journal of Chronic Obstructive Pulmonary ...
openaire   +6 more sources

Efficacy and safety of olodaterol once daily delivered via Respimat® in patients with GOLD 2–4 COPD: results from two replicate 48-week studies

International Journal of COPD, 2014
Gary T Ferguson,1 Gregory J Feldman,2 Peter Hofbauer,3 Alan Hamilton,4 Lisa Allen,5 Lawrence Korducki,5 Paul Sachs6 1Pulmonary Research Institute of Southeast Michigan, Livonia, MI, 2S Carolina Pharmaceutical Research, Spartanburg, SC, USA; 3Pneumologie,
Ferguson GT, Feldman GJ, Hofbauer P, Hamilton A, Allen L, Korducki L, Sachs P   +6 more
doaj  

COPD Maintenance Therapy with Tiotropium/Olodaterol Compared with Tiotropium: An Analysis in the Absence of Additional ICS Therapy

COPD, 2020
The American Thoracic Society guidelines recommend long-acting β2-agonist (LABA)/long-acting muscarinic antagonist (LAMA) dual bronchodilation over LAMA or LABA monotherapy as maintenance therapy for patients with chronic obstructive pulmonary disease ...
Peter M. A. Calverley, Alberto de la Hoz, Wenqiong Xue, Gary T. Ferguson, Marc Miravitlles   +4 more
doaj   +1 more source

Impact of tiotropium + olodaterol on physical functioning in COPD: results of an open-label observational study

International Journal of COPD, 2016
Rüdiger Sauer,1 Michaela Hänsel,2 Roland Buhl,3 Roman A Rubin,4 Marcel Frey,5 Thomas Glaab2,3 1Lung Centre Ulm, Ulm, Germany; 2Boehringer Ingelheim Pharma GmbH & Co.
Sauer R, Hänsel M, Buhl R, Rubin RA, Frey M, Glaab T   +5 more
doaj  

Efficacy of tiotropium/olodaterol on lung volume, exercise capacity, and physical activity

International Journal of COPD, 2018
Masakazu Ichinose,1 Yoshiaki Minakata,2 Takashi Motegi,3 Jun Ueki,4 Yasuhiro Gon,5 Tetsuo Seki,6 Tatsuhiko Anzai,7 Shuhei Nakamura,6 Kazuto Hirata8 1Department of Respiratory Medicine, Tohoku University Graduate School of Medicine, Sendai, 2Department of
Ichinose M, Minakata Y, Motegi T, Ueki J, Gon Y, Seki T, Anzai T, Nakamura S, Hirata K   +8 more
doaj  

Assessment of physical functioning and handling of tiotropium/olodaterol Respimat® in patients with COPD in a real-world clinical setting

International Journal of COPD, 2019
Karl-Otto Steinmetz,1 Birgit Abenhardt,2 Stefan Pabst,3 Michaela Hänsel,4 Anke Kondla,5 Valentina Bayer,6 Roland Buhl71LungCenter Darmstadt, Darmstadt, Germany; 2Pulmonary Practice, Heidelberg, Germany; 3Lung Center, Bonn-Duisdorf, Germany; 4TA ...
Steinmetz KO, Abenhardt B, Pabst S, Hänsel M, Kondla A, Bayer V, Buhl R   +6 more
doaj  

Efficacy and safety of tiotropium + olodaterol maintenance treatment in patients with COPD in the TONADO® and OTEMTO® studies: a subgroup analysis by age

International Journal of COPD, 2016
Gary T Ferguson,1 Jill P Karpel,2 Emmanuelle Clerisme-Beaty,3 Lars Grönke,4 Florian Voß,4 Roland Buhl5 1Pulmonary Research Institute of Southeast Michigan, Farmington Hills, MI, 2North Shore Medical Arts LLP, Great Neck, NY, 3Boehringer ...
Ferguson GT, Karpel JP, Clerisme-Beaty E, Grönke L, Voß F, Buhl R   +5 more
doaj  

Efficacy and safety of the long-acting β2-agonist olodaterol over 4 weeks in Japanese patients with chronic obstructive pulmonary disease

International Journal of COPD, 2015
Masakazu Ichinose,1 Ayako Takizawa,2 Toshiyasu Izumoto,2 Yusuke Tadayasu,2 Alan L Hamilton,3 Christina Kunz,4 Yoshinosuke Fukuchi51Department of Respiratory Medicine, Tohoku University Graduate School of Medicine, Sendai, Japan; 2Nippon Boehringer ...
Ichinose M, Takizawa A, Izumoto T, Tadayasu Y, Hamilton AL, Kunz C, Fukuchi Y   +6 more
doaj  

UK-specific cost-effectiveness of tiotropium + olodaterol fixed-dose combination versus other LAMA + LABA combinations in patients with COPD

ClinicoEconomics and Outcomes Research, 2016
Abigail Tebboth,1 Andrew Ternouth,1 Nuria Gonzalez-Rojas2 1Boehringer Ingelheim Ltd., Bracknell, UK; 2Boehringer Ingelheim GmBH, Ingelheim, Germany Objective: The aim of this study is to assess the cost-effectiveness of other long-acting muscarinic ...
Tebboth A, Ternouth A, Gonzalez-Rojas N
doaj